The BioAI Phase Shift: How Chai Discovery Is Rewriting Drug Design from Wet Labs to CAD

Chai Discovery is pioneering a shift in biopharma by using generative AI for deterministic, sub-angstrom structural engineering, replacing traditional mouse immunization in drug design. The company's software factory model could disrupt legacy drug discovery economics.

As generative AI transitions from token generation to atomic assembly, Chai Discovery is pioneering a paradigm shift in biopharma. By replacing serendipitous mouse immunization with deterministic, sub-angstrom structural engineering, Chai's software factory model threatens to dismantle legacy drug discovery economics.